Free Trial

KalVista Pharmaceuticals Q4 2023 Earnings Report

KalVista Pharmaceuticals logo
$8.36 +0.27 (+3.34%)
(As of 12/20/2024 05:16 PM ET)

KalVista Pharmaceuticals EPS Results

Actual EPS
-$0.80
Consensus EPS
-$0.76
Beat/Miss
Missed by -$0.04
One Year Ago EPS
N/A

KalVista Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

KalVista Pharmaceuticals Announcement Details

Quarter
Q4 2023
Time
N/A
Collect $7k per month from Tesla’s SECRET dividend (Ad)

Tesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69% dividend from Tesla… Which could put up to $7,013 in your pocket every month…

Click here to discover the new #1 way to invest in Tesla

KalVista Pharmaceuticals Earnings Headlines

The #1 Coin for November 2024
Grayscale Investments just announced a new fund offering access to a HOT new DeFi coin… And thanks to this newly established trust, I believe this coin could skyrocket up to 150x+ in the next 30 days alone! I've compiled everything you need to know about this once-in-a-lifetime DeFi project into a brand-new comprehensive guide…
KalVista initiated with a Buy at BofA
KalVista Pharmaceuticals Appoints New COO Amid Strategic Growth
See More KalVista Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like KalVista Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on KalVista Pharmaceuticals and other key companies, straight to your email.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals (NASDAQ:KALV), a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). It develops Factor XIIa, an oral inhibitor for the treatment of HAE which is in preclinical trial. In addition, the company is developing an orally disintegrating tablet formulation, including KONFIDENT-KID for pediatric use with HAE; KONFIDENT-S for adolescent and adult patients with type I or type II HAE; and KONFIDENT for a potential oral therapy for HAE attacks. The company is headquartered in Cambridge, Massachusetts.

View KalVista Pharmaceuticals Profile

More Earnings Resources from MarketBeat

Upcoming Earnings